Health Condition 1: G31- Other degenerative diseases of nervous system, not elsewhere classified
Conditions
Sponsors
Jaslok Hospital and Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: - The patient must have at least 6 years of education and be able to read, write, and fully understand the language of the cognitive tests (Here, English). - The patient must have a Clinical Dementia Rating (CDR) score of 0.5 and a CDR-memory score of equal to or more than 0.5. - The patient must have a Delayed Recall score of less than or equal to 10 on the New York University (NYU) Paragraph Recall test. - The patient must have sufficient visual, hearing, and communication ability with or without external aids. - The patient must also have a consistent informant to accompany them to scheduled study visits. - The patient must be fit for dTMS as per BRAINSway guidelines.
Exclusion criteria
Exclusion criteria: - The patient must not have shortness of breath while sitting. - The patient will be excluded if the investigator determines that the patient is at risk because of participation in the trial or has a physical condition that may influence the results of the trial. - The patient must not have a pacemaker or other metallic implant that is unsafe for TMS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment (MoCA)Timepoint: Just after treatment, 1 month after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Dementia Rating Scale (CDR)Timepoint: Just after treatment, 1 month after treatment;Alzheimer s Disease Assessment Scale - Cognitive subscale, adapted for use in MCI (ADAS-cog/MCI)Timepoint: Just after treatment, 1 month after treatment;Alzheimer s Disease Cooperative Study Activities of Daily Living Adapted to MCI (ADCS-ADL/MCI)Timepoint: Just after treatment, 1 month after treatment;Delayed Recall Score of the NYU Paragraph Recall TestTimepoint: Just after treatment, 1 month after treatment;Addenbrooke Cognitive Examination (ACE)Timepoint: Just after treatment, 1 month after treatment;Adverse EffectsTimepoint: During and after treatment | — |
Countries
India
Contacts
Public ContactProf Dr Paresh K Doshi
Jaslok Hospital and Research Center, Mumbai
Outcome results
None listed